| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 42 | 2015 | 4638 | 1.610 |
Why?
|
| Neoplasms, Glandular and Epithelial | 10 | 2014 | 519 | 0.830 |
Why?
|
| Genital Neoplasms, Female | 7 | 2012 | 735 | 0.610 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 2 | 2014 | 108 | 0.570 |
Why?
|
| Apoptosis | 16 | 2014 | 7591 | 0.560 |
Why?
|
| Carboplatin | 5 | 2013 | 823 | 0.520 |
Why?
|
| Receptors, Notch | 2 | 2014 | 383 | 0.470 |
Why?
|
| Polyenes | 2 | 2003 | 35 | 0.450 |
Why?
|
| Alkyl and Aryl Transferases | 2 | 2003 | 87 | 0.430 |
Why?
|
| HSP70 Heat-Shock Proteins | 2 | 2003 | 161 | 0.420 |
Why?
|
| Antineoplastic Agents | 20 | 2014 | 14289 | 0.340 |
Why?
|
| Mice, Nude | 12 | 2014 | 4307 | 0.300 |
Why?
|
| Neovascularization, Pathologic | 6 | 2015 | 1547 | 0.290 |
Why?
|
| Peritoneal Neoplasms | 5 | 2014 | 821 | 0.280 |
Why?
|
| Histones | 2 | 2013 | 1466 | 0.270 |
Why?
|
| Aurora Kinases | 4 | 2012 | 189 | 0.270 |
Why?
|
| Fallopian Tube Neoplasms | 3 | 2014 | 153 | 0.260 |
Why?
|
| Cell Line, Tumor | 21 | 2014 | 14551 | 0.260 |
Why?
|
| Uterine Cervical Dysplasia | 4 | 2005 | 219 | 0.260 |
Why?
|
| Membrane Proteins | 2 | 2014 | 2819 | 0.250 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2015 | 1533 | 0.240 |
Why?
|
| Chromosomal Instability | 1 | 2005 | 233 | 0.230 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2015 | 1248 | 0.230 |
Why?
|
| Piperazines | 1 | 2012 | 2101 | 0.230 |
Why?
|
| Drug Delivery Systems | 5 | 2008 | 669 | 0.220 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 4 | 2004 | 212 | 0.220 |
Why?
|
| Receptors, Transforming Growth Factor beta | 2 | 2004 | 229 | 0.220 |
Why?
|
| Proteomics | 3 | 2004 | 1380 | 0.220 |
Why?
|
| Enzyme Inhibitors | 4 | 2008 | 1879 | 0.210 |
Why?
|
| Female | 62 | 2015 | 141928 | 0.210 |
Why?
|
| Drug Resistance, Neoplasm | 10 | 2013 | 5178 | 0.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2014 | 15862 | 0.210 |
Why?
|
| Paclitaxel | 3 | 2014 | 1996 | 0.210 |
Why?
|
| Organoplatinum Compounds | 5 | 2013 | 702 | 0.210 |
Why?
|
| Genes, p53 | 2 | 2009 | 1090 | 0.200 |
Why?
|
| Retinoids | 1 | 2002 | 164 | 0.200 |
Why?
|
| Uterine Cervical Neoplasms | 6 | 2008 | 1833 | 0.200 |
Why?
|
| Aurora Kinase B | 2 | 2012 | 68 | 0.190 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2014 | 3821 | 0.190 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2010 | 2359 | 0.190 |
Why?
|
| Tumor Cells, Cultured | 10 | 2005 | 5395 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-raf | 2 | 2014 | 80 | 0.170 |
Why?
|
| Uterine Neoplasms | 2 | 2014 | 545 | 0.170 |
Why?
|
| Drug Synergism | 4 | 2014 | 1313 | 0.170 |
Why?
|
| Azacitidine | 4 | 2013 | 1149 | 0.170 |
Why?
|
| Organic Chemicals | 2 | 2013 | 113 | 0.170 |
Why?
|
| Blotting, Western | 8 | 2014 | 3536 | 0.170 |
Why?
|
| Interferon-gamma | 2 | 2006 | 1144 | 0.170 |
Why?
|
| Thiazoles | 2 | 2014 | 726 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2014 | 8873 | 0.160 |
Why?
|
| RNA, Small Interfering | 3 | 2014 | 2216 | 0.160 |
Why?
|
| Transforming Growth Factor beta | 2 | 2004 | 1130 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2014 | 10035 | 0.160 |
Why?
|
| Humans | 68 | 2015 | 261506 | 0.160 |
Why?
|
| Down-Regulation | 3 | 2012 | 2074 | 0.150 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2014 | 852 | 0.150 |
Why?
|
| Mitotic Index | 1 | 1997 | 162 | 0.150 |
Why?
|
| Cell Proliferation | 9 | 2014 | 7226 | 0.150 |
Why?
|
| Mice | 17 | 2014 | 34495 | 0.140 |
Why?
|
| Up-Regulation | 6 | 2005 | 2450 | 0.140 |
Why?
|
| Immunohistochemistry | 8 | 2014 | 7548 | 0.140 |
Why?
|
| Animals | 22 | 2014 | 59536 | 0.140 |
Why?
|
| Mass Spectrometry | 3 | 2004 | 702 | 0.140 |
Why?
|
| Aurora Kinase A | 2 | 2008 | 202 | 0.130 |
Why?
|
| Gene Expression Profiling | 2 | 2005 | 5159 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 8 | 2006 | 3639 | 0.130 |
Why?
|
| DNA Methylation | 6 | 2013 | 2669 | 0.130 |
Why?
|
| Kallikreins | 1 | 2014 | 84 | 0.120 |
Why?
|
| Anticarcinogenic Agents | 3 | 2005 | 362 | 0.120 |
Why?
|
| Receptor, Notch3 | 1 | 2014 | 31 | 0.120 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2014 | 69 | 0.120 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2014 | 85 | 0.120 |
Why?
|
| Dynamins | 1 | 2014 | 74 | 0.120 |
Why?
|
| Jagged-1 Protein | 1 | 2014 | 101 | 0.120 |
Why?
|
| Oleanolic Acid | 2 | 2004 | 108 | 0.120 |
Why?
|
| Leukemia, Myeloid | 3 | 2004 | 941 | 0.120 |
Why?
|
| Y-Box-Binding Protein 1 | 1 | 2013 | 36 | 0.120 |
Why?
|
| Aneuploidy | 2 | 2005 | 369 | 0.120 |
Why?
|
| Tubulin Modulators | 1 | 2013 | 65 | 0.120 |
Why?
|
| Tumor Burden | 3 | 2014 | 1987 | 0.120 |
Why?
|
| Endocytosis | 1 | 2014 | 225 | 0.110 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2014 | 134 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2014 | 4757 | 0.110 |
Why?
|
| Polyunsaturated Alkamides | 2 | 2003 | 35 | 0.110 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2013 | 111 | 0.110 |
Why?
|
| Gene Silencing | 3 | 2011 | 837 | 0.110 |
Why?
|
| Calcium-Binding Proteins | 2 | 2014 | 545 | 0.110 |
Why?
|
| Receptor, EphA2 | 1 | 2014 | 132 | 0.110 |
Why?
|
| Acetamides | 1 | 2013 | 113 | 0.110 |
Why?
|
| Farnesyltranstransferase | 2 | 2003 | 122 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 6 | 2006 | 1493 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 5 | 2014 | 4367 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2012 | 1489 | 0.110 |
Why?
|
| DNA, Neoplasm | 3 | 2013 | 1910 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2014 | 2508 | 0.110 |
Why?
|
| Cell Division | 6 | 2004 | 2489 | 0.100 |
Why?
|
| Cell Survival | 7 | 2014 | 3045 | 0.100 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2012 | 82 | 0.100 |
Why?
|
| Caspases | 2 | 2004 | 661 | 0.100 |
Why?
|
| Hyaluronan Receptors | 1 | 2012 | 249 | 0.100 |
Why?
|
| Niacinamide | 1 | 2013 | 421 | 0.100 |
Why?
|
| Thrombocytosis | 1 | 2012 | 121 | 0.100 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 1077 | 0.100 |
Why?
|
| Hyaluronic Acid | 1 | 2012 | 168 | 0.100 |
Why?
|
| src-Family Kinases | 1 | 2013 | 478 | 0.090 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 650 | 0.090 |
Why?
|
| Pyrimidines | 2 | 2014 | 3518 | 0.090 |
Why?
|
| Cell Hypoxia | 1 | 2011 | 328 | 0.090 |
Why?
|
| Adrenergic Agents | 1 | 2010 | 18 | 0.090 |
Why?
|
| Anoikis | 1 | 2010 | 63 | 0.090 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2013 | 436 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2011 | 272 | 0.090 |
Why?
|
| Stromal Cells | 2 | 2005 | 825 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2005 | 5437 | 0.090 |
Why?
|
| Cyclin B | 1 | 2009 | 63 | 0.090 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2010 | 161 | 0.090 |
Why?
|
| Biomarkers, Tumor | 5 | 2014 | 10331 | 0.080 |
Why?
|
| Signal Transduction | 7 | 2014 | 11965 | 0.080 |
Why?
|
| Patents as Topic | 1 | 2008 | 28 | 0.080 |
Why?
|
| Chondroitin | 1 | 2008 | 5 | 0.080 |
Why?
|
| PPAR gamma | 2 | 2012 | 229 | 0.080 |
Why?
|
| Transcriptome | 2 | 2014 | 1859 | 0.080 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2012 | 448 | 0.080 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2012 | 486 | 0.080 |
Why?
|
| Eflornithine | 2 | 1998 | 59 | 0.080 |
Why?
|
| Hypercalcemia | 1 | 2009 | 137 | 0.080 |
Why?
|
| Aspartic Acid | 1 | 2008 | 126 | 0.080 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2010 | 1299 | 0.080 |
Why?
|
| Clinical Trials as Topic | 3 | 2008 | 3719 | 0.080 |
Why?
|
| S Phase | 1 | 2008 | 281 | 0.080 |
Why?
|
| Interleukin-6 | 1 | 2012 | 1038 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 4 | 2012 | 3981 | 0.070 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2010 | 461 | 0.070 |
Why?
|
| Indoles | 1 | 2013 | 1009 | 0.070 |
Why?
|
| Carcinoma in Situ | 1 | 2010 | 487 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2012 | 1555 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2014 | 6207 | 0.070 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 503 | 0.070 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2014 | 1283 | 0.070 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2007 | 167 | 0.070 |
Why?
|
| Estrogens | 2 | 2007 | 751 | 0.070 |
Why?
|
| Pyridines | 1 | 2013 | 1244 | 0.070 |
Why?
|
| Aged, 80 and over | 9 | 2014 | 29902 | 0.070 |
Why?
|
| CD40 Ligand | 1 | 2006 | 115 | 0.070 |
Why?
|
| CD40 Antigens | 1 | 2006 | 104 | 0.070 |
Why?
|
| Cell Nucleus | 2 | 2009 | 1620 | 0.070 |
Why?
|
| Aged | 16 | 2014 | 70117 | 0.070 |
Why?
|
| Caspase 3 | 2 | 2004 | 471 | 0.070 |
Why?
|
| Genetic Therapy | 2 | 2011 | 1616 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2015 | 3251 | 0.070 |
Why?
|
| Middle Aged | 17 | 2014 | 86204 | 0.070 |
Why?
|
| Disease-Free Survival | 6 | 2015 | 10001 | 0.070 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 1265 | 0.070 |
Why?
|
| Fenretinide | 1 | 2005 | 96 | 0.070 |
Why?
|
| Cell Cycle Proteins | 2 | 2012 | 2045 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2004 | 324 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2013 | 1756 | 0.060 |
Why?
|
| Endothelial Cells | 1 | 2011 | 1048 | 0.060 |
Why?
|
| Aromatase Inhibitors | 1 | 2007 | 305 | 0.060 |
Why?
|
| Prostaglandin D2 | 1 | 2004 | 26 | 0.060 |
Why?
|
| Retinoid X Receptors | 1 | 2004 | 85 | 0.060 |
Why?
|
| Cadherins | 1 | 2008 | 660 | 0.060 |
Why?
|
| Phosphorylation | 5 | 2014 | 4804 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2005 | 290 | 0.060 |
Why?
|
| Receptors, Retinoic Acid | 2 | 2004 | 365 | 0.060 |
Why?
|
| Doxorubicin | 3 | 2007 | 3005 | 0.060 |
Why?
|
| Quercetin | 1 | 2003 | 16 | 0.060 |
Why?
|
| Precancerous Conditions | 1 | 2010 | 1058 | 0.060 |
Why?
|
| cdc25 Phosphatases | 2 | 2004 | 97 | 0.060 |
Why?
|
| Carcinoma | 2 | 2007 | 2578 | 0.060 |
Why?
|
| Cell Cycle | 3 | 2013 | 2084 | 0.060 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2007 | 726 | 0.060 |
Why?
|
| Databases, Protein | 1 | 2003 | 100 | 0.060 |
Why?
|
| Tumor Microenvironment | 2 | 2012 | 2864 | 0.060 |
Why?
|
| Polyethylene Glycols | 1 | 2007 | 615 | 0.060 |
Why?
|
| Hormone Antagonists | 1 | 2003 | 101 | 0.060 |
Why?
|
| Blood Proteins | 1 | 2004 | 294 | 0.060 |
Why?
|
| Receptors, Growth Factor | 1 | 2003 | 157 | 0.060 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2003 | 208 | 0.060 |
Why?
|
| Mixed Tumor, Mullerian | 1 | 2003 | 37 | 0.060 |
Why?
|
| Gene Transfer Techniques | 1 | 2006 | 716 | 0.060 |
Why?
|
| Endometrial Neoplasms | 1 | 2012 | 1341 | 0.060 |
Why?
|
| Smad4 Protein | 2 | 2004 | 196 | 0.060 |
Why?
|
| Protein Multimerization | 2 | 2014 | 240 | 0.050 |
Why?
|
| Adult | 13 | 2014 | 77950 | 0.050 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2003 | 177 | 0.050 |
Why?
|
| Genes, bcl-2 | 1 | 2002 | 166 | 0.050 |
Why?
|
| Protein Array Analysis | 1 | 2004 | 501 | 0.050 |
Why?
|
| Drug Administration Schedule | 4 | 2012 | 3472 | 0.050 |
Why?
|
| Transcription Factors | 2 | 2008 | 5270 | 0.050 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2002 | 231 | 0.050 |
Why?
|
| Models, Biological | 3 | 2007 | 3254 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2007 | 840 | 0.050 |
Why?
|
| Transplantation, Heterologous | 2 | 2003 | 1082 | 0.050 |
Why?
|
| Bone Marrow Cells | 2 | 2002 | 943 | 0.050 |
Why?
|
| Computational Biology | 2 | 2005 | 1271 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2007 | 691 | 0.050 |
Why?
|
| Proteome | 2 | 2002 | 561 | 0.050 |
Why?
|
| Camptothecin | 1 | 2003 | 517 | 0.050 |
Why?
|
| Lymphatic Metastasis | 2 | 2008 | 4844 | 0.050 |
Why?
|
| Neoplasm Proteins | 2 | 2002 | 3230 | 0.050 |
Why?
|
| Mesothelioma | 2 | 2003 | 544 | 0.050 |
Why?
|
| Research | 1 | 2002 | 415 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2004 | 591 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2014 | 2054 | 0.040 |
Why?
|
| Dasatinib | 2 | 2014 | 862 | 0.040 |
Why?
|
| DNA Primers | 3 | 2010 | 1399 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2004 | 810 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2003 | 1064 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2005 | 2232 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 2007 | 960 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2012 | 4938 | 0.040 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2013 | 289 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2004 | 4971 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2005 | 2283 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2003 | 1648 | 0.040 |
Why?
|
| RNA, Messenger | 4 | 2012 | 6150 | 0.040 |
Why?
|
| Proteins | 2 | 2004 | 1963 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2004 | 2488 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 1538 | 0.040 |
Why?
|
| Neoplasm Metastasis | 3 | 2005 | 5112 | 0.040 |
Why?
|
| ErbB Receptors | 3 | 2006 | 2295 | 0.040 |
Why?
|
| Morpholines | 2 | 2013 | 289 | 0.040 |
Why?
|
| Trans-Activators | 2 | 2004 | 1555 | 0.040 |
Why?
|
| Mitochondria | 1 | 2003 | 1282 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2002 | 2315 | 0.030 |
Why?
|
| Taxoids | 2 | 2014 | 967 | 0.030 |
Why?
|
| Leukemia | 1 | 2004 | 1635 | 0.030 |
Why?
|
| Quinazolines | 2 | 2014 | 923 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2004 | 2022 | 0.030 |
Why?
|
| Receptors, LHRH | 2 | 2007 | 41 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 1997 | 1165 | 0.030 |
Why?
|
| Disease Progression | 4 | 2010 | 6682 | 0.030 |
Why?
|
| Cisplatin | 3 | 2008 | 2432 | 0.030 |
Why?
|
| Flow Cytometry | 3 | 2006 | 3033 | 0.030 |
Why?
|
| Peritoneum | 2 | 2005 | 150 | 0.030 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2013 | 60 | 0.030 |
Why?
|
| bcl-X Protein | 2 | 2004 | 196 | 0.030 |
Why?
|
| HL-60 Cells | 2 | 2004 | 302 | 0.030 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 1 | 2013 | 47 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2015 | 2594 | 0.030 |
Why?
|
| Drug Resistance, Multiple | 2 | 2003 | 204 | 0.030 |
Why?
|
| Neoplasms | 2 | 2013 | 15193 | 0.030 |
Why?
|
| Microtubules | 1 | 2013 | 270 | 0.030 |
Why?
|
| Molecular Weight | 2 | 2003 | 629 | 0.030 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2012 | 157 | 0.030 |
Why?
|
| Thrombospondin 1 | 1 | 2012 | 55 | 0.030 |
Why?
|
| Acetylation | 1 | 2013 | 508 | 0.030 |
Why?
|
| Valproic Acid | 1 | 2013 | 263 | 0.030 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2012 | 62 | 0.030 |
Why?
|
| Oligonucleotides | 1 | 2013 | 227 | 0.030 |
Why?
|
| Thrombopoietin | 1 | 2012 | 77 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2014 | 639 | 0.020 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2012 | 217 | 0.020 |
Why?
|
| Epigenomics | 1 | 2012 | 266 | 0.020 |
Why?
|
| Transfection | 2 | 2008 | 2944 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2015 | 938 | 0.020 |
Why?
|
| Platelet Count | 1 | 2012 | 490 | 0.020 |
Why?
|
| DNA-Binding Proteins | 2 | 2004 | 4821 | 0.020 |
Why?
|
| Base Sequence | 2 | 2010 | 4917 | 0.020 |
Why?
|
| Ovarian Diseases | 1 | 2010 | 54 | 0.020 |
Why?
|
| Pyrazines | 1 | 2013 | 495 | 0.020 |
Why?
|
| Tretinoin | 2 | 2004 | 623 | 0.020 |
Why?
|
| Liposomes | 2 | 2003 | 684 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2012 | 576 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2012 | 355 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2012 | 666 | 0.020 |
Why?
|
| Cyclin G | 1 | 2009 | 10 | 0.020 |
Why?
|
| Cyclin G1 | 1 | 2009 | 11 | 0.020 |
Why?
|
| Infusions, Intravenous | 2 | 2003 | 1382 | 0.020 |
Why?
|
| Cyclin B1 | 1 | 2009 | 56 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 2 | 2004 | 848 | 0.020 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2010 | 160 | 0.020 |
Why?
|
| RNA | 2 | 2005 | 1013 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2012 | 9180 | 0.020 |
Why?
|
| Cytokines | 2 | 2012 | 2809 | 0.020 |
Why?
|
| Norepinephrine | 1 | 2010 | 272 | 0.020 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2013 | 612 | 0.020 |
Why?
|
| Epinephrine | 1 | 2010 | 255 | 0.020 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2010 | 245 | 0.020 |
Why?
|
| Breast Neoplasms | 2 | 2003 | 15694 | 0.020 |
Why?
|
| Piperidines | 1 | 2014 | 1035 | 0.020 |
Why?
|
| Cyclin A | 1 | 2008 | 47 | 0.020 |
Why?
|
| Cell Line | 2 | 2008 | 5114 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2013 | 2316 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2013 | 986 | 0.020 |
Why?
|
| Benzamides | 1 | 2013 | 1832 | 0.020 |
Why?
|
| Snail Family Transcription Factors | 1 | 2008 | 120 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2012 | 7222 | 0.020 |
Why?
|
| Aromatase | 1 | 2007 | 56 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2010 | 769 | 0.020 |
Why?
|
| Cyclins | 1 | 2009 | 456 | 0.020 |
Why?
|
| Receptors, Gonadotropin | 1 | 2007 | 4 | 0.020 |
Why?
|
| Acute Disease | 2 | 2002 | 2422 | 0.020 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2007 | 105 | 0.020 |
Why?
|
| Actins | 1 | 2010 | 608 | 0.020 |
Why?
|
| Gonadotropins | 1 | 2007 | 50 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2012 | 731 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 1258 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2008 | 528 | 0.020 |
Why?
|
| Thionucleotides | 1 | 2006 | 65 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2002 | 3976 | 0.020 |
Why?
|
| Transcription, Genetic | 2 | 2005 | 3154 | 0.020 |
Why?
|
| Gene Expression | 1 | 2014 | 3570 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2006 | 342 | 0.020 |
Why?
|
| Cytarabine | 2 | 2002 | 1973 | 0.020 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2006 | 248 | 0.020 |
Why?
|
| Mitosis | 1 | 2007 | 615 | 0.020 |
Why?
|
| Agar | 1 | 2004 | 26 | 0.020 |
Why?
|
| Retinoic Acid Receptor alpha | 1 | 2004 | 95 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2014 | 6100 | 0.020 |
Why?
|
| U937 Cells | 1 | 2004 | 171 | 0.020 |
Why?
|
| Placebos | 1 | 2005 | 437 | 0.020 |
Why?
|
| bcl-Associated Death Protein | 1 | 2004 | 26 | 0.020 |
Why?
|
| Progesterone | 1 | 2007 | 513 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2013 | 1823 | 0.020 |
Why?
|
| Dimerization | 1 | 2004 | 304 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2004 | 311 | 0.010 |
Why?
|
| Chromones | 1 | 2004 | 120 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2003 | 43 | 0.010 |
Why?
|
| Growth Inhibitors | 1 | 2004 | 149 | 0.010 |
Why?
|
| Endometrial Stromal Tumors | 1 | 2003 | 7 | 0.010 |
Why?
|
| Androgens | 1 | 2007 | 511 | 0.010 |
Why?
|
| Retrospective Studies | 4 | 2009 | 37905 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2003 | 6915 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2004 | 367 | 0.010 |
Why?
|
| Thiazolidinediones | 1 | 2004 | 148 | 0.010 |
Why?
|
| Technetium | 1 | 2003 | 77 | 0.010 |
Why?
|
| Trastuzumab | 1 | 2006 | 696 | 0.010 |
Why?
|
| Phagocytosis | 1 | 2004 | 260 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2003 | 197 | 0.010 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2004 | 170 | 0.010 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2003 | 119 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2005 | 869 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2008 | 2314 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 4988 | 0.010 |
Why?
|
| Treatment Outcome | 3 | 2014 | 32848 | 0.010 |
Why?
|
| Bridged-Ring Compounds | 1 | 2003 | 183 | 0.010 |
Why?
|
| Topotecan | 1 | 2003 | 239 | 0.010 |
Why?
|
| Zinc Fingers | 1 | 2003 | 205 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 2002 | 74 | 0.010 |
Why?
|
| Thalidomide | 1 | 2006 | 569 | 0.010 |
Why?
|
| Ascites | 1 | 2003 | 198 | 0.010 |
Why?
|
| Plasmids | 1 | 2004 | 837 | 0.010 |
Why?
|
| Retroviridae | 1 | 2003 | 332 | 0.010 |
Why?
|
| Annexin A2 | 1 | 2002 | 15 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2004 | 553 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 2003 | 660 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2012 | 5710 | 0.010 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2003 | 170 | 0.010 |
Why?
|
| beta 2-Microglobulin | 1 | 2002 | 184 | 0.010 |
Why?
|
| Peptide Mapping | 1 | 2002 | 114 | 0.010 |
Why?
|
| Annexin A1 | 1 | 2002 | 39 | 0.010 |
Why?
|
| Fibrinolytic Agents | 1 | 2004 | 324 | 0.010 |
Why?
|
| Ligands | 1 | 2004 | 995 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2003 | 875 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2003 | 700 | 0.010 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2002 | 87 | 0.010 |
Why?
|
| Subtraction Technique | 1 | 2002 | 141 | 0.010 |
Why?
|
| Receptors, Steroid | 1 | 2003 | 286 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 2005 | 554 | 0.010 |
Why?
|
| fas Receptor | 1 | 2002 | 185 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 4744 | 0.010 |
Why?
|
| CpG Islands | 1 | 2003 | 633 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2006 | 2927 | 0.010 |
Why?
|
| Ovary | 1 | 2005 | 668 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 2002 | 593 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2004 | 1764 | 0.010 |
Why?
|
| Immunologic Factors | 1 | 2004 | 649 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2003 | 842 | 0.010 |
Why?
|
| Blast Crisis | 1 | 2003 | 557 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2004 | 1070 | 0.010 |
Why?
|
| Cell Movement | 1 | 2008 | 2466 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2002 | 459 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2003 | 598 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2007 | 2086 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2002 | 771 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2002 | 1008 | 0.010 |
Why?
|
| Forecasting | 1 | 2002 | 694 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2012 | 2947 | 0.010 |
Why?
|
| Imidazoles | 1 | 2004 | 999 | 0.010 |
Why?
|
| Incidence | 1 | 2009 | 5673 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2006 | 3890 | 0.010 |
Why?
|
| Testosterone | 1 | 2003 | 619 | 0.010 |
Why?
|
| Image Cytometry | 1 | 1997 | 47 | 0.010 |
Why?
|
| Neutropenia | 1 | 2001 | 968 | 0.010 |
Why?
|
| Alleles | 1 | 2003 | 2437 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2003 | 1678 | 0.010 |
Why?
|
| Cervix Uteri | 1 | 1998 | 253 | 0.010 |
Why?
|
| Receptor, ErbB-2 | 1 | 2006 | 2518 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2001 | 846 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2002 | 1242 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2003 | 3101 | 0.010 |
Why?
|
| Anemia | 1 | 2001 | 689 | 0.010 |
Why?
|
| Neoplasm Staging | 2 | 2003 | 13658 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2002 | 4233 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 1997 | 980 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 6009 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 1997 | 604 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 6089 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2004 | 4078 | 0.010 |
Why?
|
| Male | 3 | 2013 | 123000 | 0.010 |
Why?
|
| Prognosis | 1 | 2010 | 21713 | 0.010 |
Why?
|
| Risk Factors | 1 | 2007 | 17523 | 0.010 |
Why?
|
| Time Factors | 1 | 2003 | 12926 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2003 | 3578 | 0.000 |
Why?
|
| Biomarkers | 1 | 1998 | 5047 | 0.000 |
Why?
|
| Adenocarcinoma | 1 | 2003 | 7789 | 0.000 |
Why?
|